<DOC>
	<DOCNO>NCT02692963</DOCNO>
	<brief_summary>The Bacillus Calmette-Guérin ( BCG ) vaccine , live attenuate Mycobacterium bovis vaccine , use prevent tuberculosis almost century , still use vaccine world . There also circumstantial indirect evidence BCG vaccination protect malaria . Investigators hypothesize BCG vaccination offer protection malaria Controlled Human Malaria Infection ( CHMI ) model . A total 20 healthy male female volunteer participate randomize , single-blind clinical trial . Volunteers randomize receive either BCG vaccination ( BCG vaccine SSI ) ( group 1 , n=10 ) treatment ( group 2 , n=10 ) . Five week vaccination group 1 volunteer , volunteer undergo CHMI administer bite five P. falciparum infect Anopheles mosquito .</brief_summary>
	<brief_title>Safety Protective Efficacy BCG Vaccination Against Controlled Human Malaria Infection</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subject age ≥18 ≤35 year good health . 2 . Subject adequate understanding procedure study agrees abide strictly thereby . 3 . Subject able communicate well investigator available attend study visit . 4 . The subject remain within Netherlands challenge period , travel malariaendemic area study period , reachable ( 24/7 ) mobile telephone throughout entire study period . 5 . Subject agree inform his/her general practitioner participation study sign request release General Practitioner ( GP ) , medical specialist necessary , relevant medical information concern possible contraindication participation study . 6 . The subject agree refrain blood donation Sanquin purpose throughout study period define period thereafter accord current Sanquin guideline . 7 . For female subject : subject agree use adequate contraception breastfeed duration study . 8 . Subject agree refrain intensive physical exercise ( disproportionate subject usual daily activity exercise routine ) malaria challenge period . 9 . Subject sign informed consent . 1 . Any history , evidence screening , clinically significant symptom , physical sign abnormal laboratory value suggestive systemic condition , cardiovascular , pulmonary , renal , hepatic , neurological , dermatological , endocrine , malignant , haematological , infectious , immunodeficient , psychiatric disorder , could compromise health volunteer study interfere interpretation study result . These include , limited , follow . 1.1 Body weight &lt; 50 kg Body Mass lndex ( BM l ) &lt; 18 &gt; 30 kg/m2 screening . 1.2 A heighten risk cardiovascular disease , determine : estimate ten year risk fatal cardiovascular disease &gt; 5 % screening , determine Systematic Coronary Risk Evaluation ( SCORE ) ; history , evidence screening , clinically significant arrhythmia 's , prolong QTinterval clinically relevant ECG abnormality ; positive family history cardiac event 1st 2nd degree relative &lt; 50 year old . 1.3 A medical history functional asplenia , sickle cell trait disease , thalassaemia trait/disease G6PD deficiency . 1.4 History epilepsy period five year prior study onset , even long medication . 1.5 Screening test positive Human immunodeficiency Virus ( HlV ) , active Hepatitis B Virus ( HBS ) Hepatitis C Virus ( HCV ) . 1.6 Chronic use ) immunosuppressive drug , ii ) antibiotic , iii ) immune modify drug within three month prior study onset ( inhaled topical corticosteroid oral antihistamine exempt ) expect use study period . 1.7 Use Nonsteroidal Antiinflammatory Drugs ( NSAlDs ) four week prior study start expect use NSAIDS study period . 1.8 History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year . 1.9 Any history treatment severe psychiatric disease psychiatrist past year . 1.10 History drug alcohol abuse interfere normal social function period one year prior study onset , positive urine toxicology test cocaine amphetamine screen prior infection , positive urine toxicology test cannabis inclusion . 2 . For female subject : positive urine pregnancy test screen inclusion . 3 . Any history malaria , positive serology P. falciparum , previous participation malaria ( vaccine ) study . 4 . Known hypersensitivity contraindication ( include comedication ) use chloroquine , Malarone artemetherlumefantrine , history severe ( allergic ) reaction mosquito bite . 5 . Receipt vaccination 3 month prior start study plan receive vaccination study period 90 day thereafter . 6 . Participation clinical study 30 day prior start study study period . 7 . Being employee student department Medical Microbiology Radboudumc department lnternal Medicine . 8 . Previous BCGvaccination ; history tuberculosis positive Mantoux test ; positive whole blood interferongamma ( IFNγ ) response restimulation M. tuberculosis screening . 9 . Any condition situation would , opinion investigator , place subject unacceptable risk injury render subject unable meet requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>